Head to Head Analysis: CERo Therapeutics (NASDAQ:CERO) & Cardiol Therapeutics (NASDAQ:CRDL)

CERo Therapeutics (NASDAQ:CERO) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations and institutional ownership.

Volatility & Risk

CERo Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Institutional and Insider Ownership

29.6% of CERo Therapeutics shares are held by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are held by institutional investors. 0.4% of CERo Therapeutics shares are held by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares CERo Therapeutics and Cardiol Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CERo Therapeutics	N/A	N/A	-$8.30 million	($102.61)	0.00
Cardiol Therapeutics	N/A	N/A	-$26.77 million	($0.30)	-4.67

Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CERo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CERo Therapeutics and Cardiol Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CERo Therapeutics	N/A	N/A	-209.40%
Cardiol Therapeutics	N/A	-217.53%	-153.67%

Analyst Ratings

This is a summary of recent recommendations and price targets for CERo Therapeutics and Cardiol Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CERo Therapeutics	1	2	0	0	1.67
Cardiol Therapeutics	1	0	1	0	2.00

CERo Therapeutics currently has a consensus price target of $45.00, indicating a potential upside of 128,839.83%. Cardiol Therapeutics has a consensus price target of $9.00, indicating a potential upside of 542.86%. Given CERo Therapeutics’ higher possible upside, equities analysts clearly believe CERo Therapeutics is more favorable than Cardiol Therapeutics.

Summary

Cardiol Therapeutics beats CERo Therapeutics on 6 of the 11 factors compared between the two stocks.

About CERo Therapeutics

CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.